India, June 29 -- Larimar Therapeutics, Inc. (LRMR) stock fell 17.35 percent, declining $0.635 to $3.025 on Monday, despite the company announcing the submission of the first module of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration for accelerated approval of nomlabofusp, its investigational treatment for Friedreich's ataxia.
The stock is currently trading at $3.025, compared with its previous close of $3.66 on the Nasdaq. Shares opened at $2.97 and traded between $2.92 and $3.30 during the session. Trading volume reached 9.52 million shares, well above the average daily volume of 1.82 million shares.
Larimar said the FDA indicated during a pre-BLA meeting that its existing data package appears su...